Zobrazeno 1 - 10 of 21 pro vyhledávání: '"Sylvia McCulloch"'
1
Akademický článek
Doxycycline Plus Bortezomib-Containing Regimens for the Treatment of Light-Chain Amyloidosis in the Frontline Setting: Experience from the Amyloidosis Program of Calgary
Autor: Ellen Lewis, Nowell Fine, Sylvia McCulloch, Jason Tay, Peter Duggan, Paola Neri, Nizar Bahlis, Victor H. Jimenez-Zepeda
Publikováno v: Current Oncology, Vol 31, Iss 9, Pp 5608-5616 (2024)
Background: Pre-clinical and retrospective data suggest that doxycycline added to treatment regimens has benefit in AL amyloidosis. However, a recent multicenter, open-label, randomized controlled trial in AL amyloidosis patients treated with CyBorD
Externí odkaz: https://doaj.org/article/3a06596a38654a66af102f797b94abb0
Zobrazit plný text záznamu
2
Akademický článek
Impact of COVID-19 on the Diagnosis and Management of Multiple Myeloma: Experience from a Canadian Center
Autor: Victor H. Jiménez-Zepeda, Patrick Yau, Douglas Stewart, Jowher Berhan, Carole Chambers, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar Bahlis
Publikováno v: Revista de Investigación Clínica, Vol 74, Iss 1 (2022)
Background: The impact of coronavirus disease-19 on the management of multiple myeloma (MM) has been recognized. However, the real effect on clinical outcomes remains poorly understood. Objective: We describe a local experience of the management of M
Externí odkaz: https://doaj.org/article/24d22422a2b54a8095061b7749b6d767
Zobrazit plný text záznamu
3
Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone
Autor: Chunpeng Nie, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J Bahlis, Victor H Jimenez-Zepeda
Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 23:104-111
Higher cumulative dose of bortezomib, a key component of Multiple Myeloma (MM) treatment regimens, has been shown to improve outcomes in MM patients, but must be balanced with toxicities including peripheral neuropathy. In this study, we studied the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7467032a5a10a42c67b7f70e8f23f06
https://doi.org/10.1016/j.clml.2022.10.005
Zobrazit plný text záznamu
5
N-Terminal pro-brain natriuretic peptide (NTproBNP) in patients with symptomatic multiple myeloma: report from a single institution
Autor: Victor H Jimenez-Zepeda, Paola Neri, Nizar J. Bahlis, Sylvia McCulloch, Holly Lee, Peter Duggan, Jason Tay
Publikováno v: Annals of Hematology. 100:2521-2527
Elevated levels of serum cardiovascular markers including natriuretic peptides (NPs) such as amino terminal pro-brain natriuretic peptide (NTproBNP) have been associated with disease severity and survival in cancer patients and more recently in multi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b7631980cc5e2f793304605c127247
https://doi.org/10.1007/s00277-021-04591-z
Zobrazit plný text záznamu
6
Amyloidosis and COVID-19: experience from an amyloid program in Canada
Autor: Ellen Lewis, Nowell Fine, Robert J. H. Miller, Christopher Hahn, Sameer Chhibber, Etienne Mahe, Jason Tay, Peter Duggan, Sylvia McCulloch, Nizar Bahlis, Paola Neri, Victor H. Jimenez-Zepeda
Publikováno v: Annals of hematology. 101(10)
Severe acute respiratory syndrome coronavirus (SARS-CoV2) and associated COVID-19 infection continue to impact patients globally. Patients with underlying health conditions are at heightened risk of adverse outcomes from COVID-19; however, research i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcbdb52e36b9571b5a1124409d920ffa
https://pubmed.ncbi.nlm.nih.gov/36028582
Zobrazit plný text záznamu
8
The impact of COVID‐19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single‐center experience
Autor: Sylvia McCulloch, Jason Tay, Paola Neri, Nizar J. Bahlis, Holly Lee, Victor H Jimenez-Zepeda, Peter Duggan
Publikováno v: European Journal of Haematology
Introduction Patients with AL amyloidosis and immunoglobulin deposition diseases (IDD) are vulnerable during the COVID‐19 pandemic due to the immune compromise from the plasma cell disorder and therapy‐related immune defects. We describe a local
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b224d0cb084627e057729bb3b537f2ff
https://doi.org/10.1111/ejh.13552
Zobrazit plný text záznamu
10
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis
Autor: Peter Duggan, Paola Neri, Nizar J. Bahlis, Victor H Jimenez-Zepeda, Jason Tay, Holly Lee, Sylvia McCulloch
Publikováno v: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 28(3)
The assessment of AL amyloidosis response is based on serum free light chains (sFLC) levels, and serum and urine monoclonal protein investigations. Recently, difference between involved and uninvolved free light chains (dFLC), involved free light cha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9133ac84b436e06dc578054fd65707fc
https://pubmed.ncbi.nlm.nih.gov/34096429
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje